STADA Arzneimittel AG (SAZ) PT Set at €76.00 by Independent Research GmbH
STADA Arzneimittel AG (ETR:SAZ) received a €76.00 ($90.48) price target from Independent Research GmbH in a research note issued to investors on Tuesday. The firm presently has a “sell” rating on the stock.
Several other research analysts also recently weighed in on the stock. Commerzbank Ag set a €66.25 ($78.87) price target on shares of STADA Arzneimittel AG and gave the stock a “sell” rating in a research report on Tuesday, August 22nd. Warburg Research set a €66.25 ($78.87) price target on shares of STADA Arzneimittel AG and gave the stock a “sell” rating in a research report on Friday, August 18th. S&P Global set a €66.25 ($78.87) price target on shares of STADA Arzneimittel AG and gave the stock a “neutral” rating in a research report on Thursday, August 3rd. Finally, Kepler Capital Markets set a €66.00 ($78.57) price target on shares of STADA Arzneimittel AG and gave the stock a “neutral” rating in a research report on Tuesday, July 11th. Three equities research analysts have rated the stock with a sell rating and two have assigned a hold rating to the company. The company has a consensus rating of “Sell” and a consensus price target of €68.15 ($81.13).
STADA Arzneimittel AG (ETR SAZ) opened at 78.90 on Tuesday. STADA Arzneimittel AG has a 52-week low of €41.40 and a 52-week high of €84.20. The firm has a market cap of €4.91 billion and a P/E ratio of 52.15. The stock has a 50 day moving average price of €67.15 and a 200 day moving average price of €62.43.
STADA Arzneimittel AG Company Profile
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.
Receive News & Ratings for STADA Arzneimittel AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel AG and related companies with Analyst Ratings Network's FREE daily email newsletter.